MMV's pipeline of antimalarial drugs
Download the MMV-supported projects slide and the Global Portfolio of Antimalarial Medicines slide.
For more information about the global malaria portfolio, read the article: Malaria medicines: a glass half full?
Detailed information is available for translational, development and access projects (click on the boxes below).
Last updated June 2022
MMV support to projects may include financial, in-kind, and advisory activities.
Global Fund Expert Review Panel (ERP) reviewed product – permitted for time-limited procurement, while regulatory/WHO prequalification review is ongoing.
Included in MMV portfolio after product approval and/or development. DNDi and partners completed development and registration of ASMQ and ASAQ.
WHO Prequalified OR approved/positive opinion by regulatory bodies who are ICH members/observers.
Via a bioequivalence study.
No progress report in the last two years.
Past partners are in brackets (-)
1 Coartem® Dispersible
3 Larinate® 60 mg
5 Pyramax® tablets or granules
6 ASAQ Winthrop®
9 100 mg Artesunate Rectocaps
11 Kozenis or Krintafel (Trademarks owned or licensed by GSK)
Target Product Profiles indicated by colour bars at the bottom of each coumpound box
____ 3-day cure, artemisinin-based combination therapies (TPP-1)
____ Uncomplicated malaria treatments and resistance management (TPP-1)
____ Severe malaria treatment / pre-referral intervention (TPP-1)
____ Intermittent preventative treatment (TPP-1)
____ Products targeting prevention of relapse for P. vivax (TPP-1)
____ Chemoprophylaxis (TPP-2)
Target Candidate Profiles activities for each individual molecule, indicated by symbols added to compounds in the translational or product development portfolio
Asexual blood stages